Centre Léon Bérard

Site:	Centre Léon Bérard
Address:	28 rue Laennec
City:	Lyon
State:	Rhone
Zip:	69373
Country:	France

24 trials at this site

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)	Active, not recruiting	Closed	Pembrolizumab + Cyclophosphamide	NCT02406781
2	Ph II CABOGIST in GIST	Active, not recruiting	Closed	Cabozantinib	NCT02216578
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
3	Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance	Completed	Closed	Imatinib	NCT00367861
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
2	Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)	Completed	Closed	Pazopanib (Votrient)	NCT01323400
2	Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)	Completed	Active	Regorafenib (SDH)	NCT02638766
1	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers	Completed	Closed	Masitinib, (AB1010)
1	A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BKM120	NCT01468688
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)	Ongoing, but not recruiting	Closed	Palbociclib	NCT01907607
3	Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)	Recruiting	Active	Imatinib	NCT02260505
2	Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)	Recruiting	Active	Lenvatinib	NCT04193553
2	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	Recruiting	Active	Imatinib	NCT05009927
2	A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)	Recruiting	Active	Imatinib + Atezolizumab	NCT05152472

Centre Léon Bérard

24 trials at this site

Page 1 of 2 | Next | Last